Literature DB >> 33572396

Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic Response.

Elisa C Toffoli1, Abdolkarim Sheikhi1,2, Yannick D Höppner1, Pita de Kok1, Mahsa Yazdanpanah-Samani3, Jan Spanholtz4, Henk M W Verheul5, Hans J van der Vliet1,6, Tanja D de Gruijl1.   

Abstract

Natural Killer (NK) cells are innate immune cells with the unique ability to recognize and kill virus-infected and cancer cells without prior immune sensitization. Due to their expression of the Fc receptor CD16, effector NK cells can kill tumor cells through antibody-dependent cytotoxicity, making them relevant players in antibody-based cancer therapies. The role of NK cells in other approved and experimental anti-cancer therapies is more elusive. Here, we review the possible role of NK cells in the efficacy of various anti-tumor therapies, including radiotherapy, chemotherapy, and immunotherapy, as well as the impact of these therapies on NK cell function.

Entities:  

Keywords:  NK cells; anti-cancer therapies; cancer; checkpoint inhibitors; chemotherapy; local ablation therapies; oncolytic virus; protein kinase inhibitors; radiotherapy

Year:  2021        PMID： 33572396      PMCID： PMC7916216          DOI： 10.3390/cancers13040711

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN： 2072-6694            Impact factor:   6.639


  226 in total

1.  Changes in peripheral blood lymphocyte subsets in patients undergoing radiotherapy.

Authors:  H Louagie; M Van Eijkeren; J Philippe; H Thierens; L de Ridder
Journal:  Int J Radiat Biol       Date:  1999-06       Impact factor: 2.694

Review 2.  Immunological aspects of cancer chemotherapy.

Authors:  Laurence Zitvogel; Lionel Apetoh; François Ghiringhelli; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2008-01       Impact factor: 53.106

Review 3.  Up on the tightrope: natural killer cell activation and inhibition.

Authors:  Lewis L Lanier
Journal:  Nat Immunol       Date:  2008-05       Impact factor: 25.606

4.  The relationship of chemotherapeutic and endocrine intervention on natural killer cell activity in human breast cancer.

Authors:  B G Brenner; R G Margolese
Journal:  Cancer       Date:  1991-08-01       Impact factor: 6.860

5.  Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma.

Authors:  Liyun Xu; Yanyan Huang; Linlin Tan; Wei Yu; Dongdong Chen; ChangChang Lu; Jianying He; Guoqing Wu; Xiaoguang Liu; Yongkui Zhang
Journal:  Int Immunopharmacol       Date:  2015-10-01       Impact factor: 4.932

Review 6.  Proteasome inhibitors in cancer therapy.

Authors:  Elisabet E Manasanch; Robert Z Orlowski
Journal:  Nat Rev Clin Oncol       Date:  2017-01-24       Impact factor: 66.675

7.  Activated anti-tumor immunity in cancer patients after high intensity focused ultrasound ablation.

Authors:  Feng Wu; Zhi-Biao Wang; Pei Lu; Zhong-Li Xu; Wen-Zhi Chen; Hui Zhu; Cheng-Bing Jin
Journal:  Ultrasound Med Biol       Date:  2004-09       Impact factor: 2.998

8.  Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo.

Authors:  Henry Ogbomo; Franz J Zemp; Xueqing Lun; Jiqing Zhang; Danuta Stack; Masmudur M Rahman; Grant McFadden; Christopher H Mody; Peter A Forsyth
Journal:  PLoS One       Date:  2013-06-10       Impact factor: 3.240

9.  Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells.

Authors:  Estefanía Paula Juliá; Analía Amante; María Betina Pampena; José Mordoh; Estrella Mariel Levy
Journal:  Front Immunol       Date:  2018-09-20       Impact factor: 7.561

Review 10.  Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.

Authors:  Nayoung Kim; Hun Sik Kim
Journal:  Front Immunol       Date:  2018-09-10       Impact factor: 7.561
View more
  6 in total

1.  Gamma-ray irradiation modulates PGRMC1 expression and the number of CD56+ and FoxP3+ cells in the tumor microenvironment of endometrial endometrioid adenocarcinoma.

Authors:  Dmitry Aleksandrovich Zinovkin; Yulia Anatolievna Lyzikova; Eldar Arkadievich Nadyrov; Daniil Rudolfovich Petrenyov; Jale Yuzugulen; Md Zahidul Islam Pranjol
Journal:  Radiat Oncol J       Date:  2021-08-17

Review 2.  Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges.

Authors:  Alessandro Poggi; Maria Raffaella Zocchi
Journal:  Mol Ther Oncolytics       Date:  2021-11-29       Impact factor: 7.200

3.  Enhancement of NK Cell Antitumor Effector Functions Using a Bispecific Single Domain Antibody Targeting CD16 and the Epidermal Growth Factor Receptor.

Authors:  Elisa C Toffoli; Abdolkarim Sheikhi; Roeland Lameris; Lisa A King; Amanda van Vliet; Bruce Walcheck; Henk M W Verheul; Jan Spanholtz; Jurriaan Tuynman; Tanja D de Gruijl; Hans J van der Vliet
Journal:  Cancers (Basel)       Date:  2021-10-29       Impact factor: 6.639

Review 4.  Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs.

Authors:  Cristina Capuano; Chiara Pighi; Simone Battella; Davide De Federicis; Ricciarda Galandrini; Gabriella Palmieri
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

Review 5.  CAR-NK Cells in the Treatment of Solid Tumors.

Authors:  Ewa Wrona; Maciej Borowiec; Piotr Potemski
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

Review 6.  Anesthesia Techniques and Long-Term Oncological Outcomes.

Authors:  Maria F Ramirez; Juan P Cata
Journal:  Front Oncol       Date:  2021-12-08       Impact factor: 6.244
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.